US-based biopharmaceutical company Biohaven Pharmaceutical Holding Company Ltd has opted to issue two million shares of its common stock in a public offering.
The shares will be issued by the selling shareholders of the company.
Maples and Calder has been appointed as legal advisor to the company for the transaction.
French biopharmaceutical company Cellectis SA plans to issue American depositary shares (ADS) in an underwritten public offering to raise $175m.
The company will grant underwriters a 30-day option to buy 26.2 million additional ADSs.
Cellectis plans to use the funds for establishing commercial capabilities, and developing additional UCART product candidate and new human therapeutics.
Australian biopharmaceutical company Antisense Therapeutics Ltd plans to issue 187.5 million shares priced at A$0.024 ($0.018) a share in a rights offering to raise A$4.5m ($3.45m).
The company has simultaneously announced plans to issue 24.2 million shares priced at A$0.024 ($0.018) each in a private placement to raise A$580,000 ($440,000).
Antisense Therapeutics plans to use proceeds for the completion of phase two clinical trial of ATL1102 in Duchenne Muscular Dystrophy patients, and for conducting ATL1103 early access programme.
The company has appointed XEC Partners as lead manager for the transaction.
US-based biotechnology company Poseida Therapeutics , Inc has raised $30.5m in an oversubscribed series B financing round.
Poseida Therapeutics plans to use funds to develop a pipeline of autologous and allogeneic CAR-T immunotherapies and gene therapies using gene engineering technologies.
US-based biotechnology company Allogene Therapeutics Inc has agreed to raise $300m in a series A financing round.
Pfizer will own 25% ownership in Allogene Therapeutics following the transaction.
Centerview Partners LLC has been appointed as financial advisor and Ropes & Gray LLP as legal advisor by Pfizer, while Cooley LLP has been appointed as legal advisor to Allogene, Vida Venture and TPG .
CMIC Cmo Co Ltd has issued shares in a private placement to raise $79.78m.
Development Bank of Japan Inc will subscribe to the placement.
CMIC CMO plans to use the funds for meeting clients’ expectations, and to speed up the expansion of its CDMO business.
US-based pharmaceutical company RXi Pharmaceuticals Corp plans to issue securities in one or more offerings to raise $100m.
The offering may include common stock, preferred stock, debt securities, warrants and units.
RXi plans to use proceeds for general corporate purposes such as funding pre-clinical and clinical activities and other research and development (R&D) activities.
The company has appointed Gibson, Dunn & Crutcher LLP as legal advisor for the transaction.
US-based pharmaceutical company Audentes Therapeutics Inc plans to issue securities in one or more offerings to raise $150m.
Audentes Therapeutics plans to use funds for general corporate purposes including R&D, expansion of production capabilities, and for acquisitions or investments in businesses.
The company has appointed Fenwick & West LLP as legal advisor for the transaction.
bioMerieux is a biotechnology company, while Astute Medical is a developer of biomarkers. Both parties are based in the US.
BioMatrix is a pharmacy platform company that focuses on both infused and oral specialty drugs, while Decillion Healthcare is a provider of individualised pharmacy and clinical support services. Both companies are US-based.
The acquisition enables BioMatrix to expand its footprint to 12 specialty pharmacy locations and to serve more than 1,700 patients across a range of therapeutic categories.
Element Genomics is a biotechnology company and a spin-off from Duke University .
Element Genomics’ team will continue to operate from downtown Durham, North Carolina, and seek guidance from Duke University and the Element Genomics founders. The company will also work in collaboration with UCB’s international research teams, upon completion of the acquisition.
The acquisition will strengthen UCB’s genomics and epigenomics research platform to identify novel drug targets.